The placebo response is conventionally asserted to be high in chronic fatigue syndrome (CFS) because of the latter's subjective nature and obscure pathogenesis, but no systematic review of placebo responses has been undertaken. We report such a study. Patient expectation is known to be important in the placebo response. It is also known that CFS patients attending specialist clinics often have strong physical attributions regarding causation and hence skepticism about psychological or psychiatric interventions. If so, the placebo response in CFS may be influenced by the type of intervention according to its perceived rationale. We aimed to estimate the summary placebo response in clinical trials of CFS and to determine whether intervention type influences the placebo response in CFS. Methods: We searched Medline, Embase, Cochrane Library, PsychInfo, and the references of the identified articles, and contacted experts for controlled trials (randomized or nonrandomized) of any intervention on CFS patients reporting the placebo response as a clinical improvement in physical or general outcomes. Data were extracted from the articles and validity assessment conducted by one reviewer and checked by a second. Meta-analysis and metaregression were performed. Results: The pooled placebo response was 19.6% (95% confidence interval, 15.4 -23.7), lower than predicted and lower than in some other medical conditions. The meta-regression revealed that intervention type significantly contributed to the heterogeneity of placebo response (p ϭ .03). Conclusion: In contrast with the conventional wisdom, the placebo response in CFS is low. Psychological-psychiatric interventions were shown to have a lower placebo response, perhaps linked to patient expectations.
INTRODUCTION
T he placebo has been defined as "any therapeutic procedure which has an effect on a patient, symptom, syndrome or disease, but which is objectively without specific activity for the condition being treated" (1) . Similarly, the placebo effect can be described as "any effect attributable to a pill, potion, or procedure, but not to its pharmacodynamic or specific properties" (2) . In order to quantify the placebo effect in clinical trials, we used the term placebo response, operationally defined as the proportion of responders in a placebo arm.
The placebo response has been classically considered as the rough proportion of one third in many illnesses after the publication of a review article by Henry K. Beecher in 1955 (35.2%) (3) . The response rates computed in recent metaanalyses seem to be in a reasonable accordance with this classic one third. A systematic review of the clinical trials for major depression has estimated the placebo response as 29.7% (4) . A similar approach to the treatment of duodenal ulcer suggests a healing rate of 44.2% in trials with a frequency of placebo administration four times a day and 36.2% in trials with administration twice a day (5) . Other examples are 29.0% in the acute treatment of migraine (6) and 26.8% in the treatment of reflux esophagitis (7) .
Several psychological and biological explanations for the placebo effect have been proposed. Two psychological theories have been widely invoked: the classic conditioning theory and the expectation theory (8) . The former suggests that the placebo effect is a conditioned response because of repeated associations between a conditioned stimulus (a placebo event such as the color or shape of an active drug) and an unconditioned stimulus (the active element capable of eliciting therapeutic responses) (9 -11) .
According to the expectation theory, the patient's expectation and belief of a positive result-or negative when we deal with the nocebo phenomenon-triggers the placebo response (12) (13) (14) (15) . In studies with alcohol or caffeine, subjects experience effects according to what they expect from the substance given (14, 16) . Expectation is also associated with the nocebo phenomenon, in which patients who expect distressing side effects before taking a medication are more likely to develop them (17) . A systematic review confirmed the importance of expectation in the placebo effect and recommended its sensible use in health care (18) . Researchers have long argued either for one or for the other theory (11, 12) . However, it is possible and even more convincing to reconcile both theories: some recent refinements of the Pavlovian theory suggest that what is learned in Pavlovian conditioning is in fact an expectation (19) .
Chronic fatigue syndrome (CFS) is characterized by severe physical and mental fatigue. The fatigue cannot be explained by any other medical condition, and the minimum duration required is 6 months (20) . This main symptom is usually accompanied by other symptoms such as muscle pain, joint pain, sleep disturbance, impaired memory, mood disturbance, and headache.
Placebos seem to work best in highly subjective symptoms usually lacking identifiable physiologic correlates, in chronic conditions with a fluctuating nature often influenced by patients' selective attention, and in affective disorders (21, 22) . These symptoms or conditions include chronic pain, fatigue, arthritis, headache, allergies, insomnia, asthma, chronic digestive disorders, depression, and anxiety (21) . Almost all the symptoms of CFS described could be categorized in one of the listed conditions or symptoms. The fatigue observed in CFS is essentially a subjective and fluctuating symptom lacking objective, physiological abnormalities, ostensibly a perfect soil where placebos may yield an enhanced effect.
It is therefore not surprising that many believe that the placebo effect is unusually high in CFS. For example, in 1997, a draft of clinical practice guidelines, citing several existing studies until that date, suggested "at least 30% to 50% of people with CFS typically demonstrate improvement in the nonspecific (or 'placebo') treatment arm of controlled trials" (23) . A number of nonsystematic reviews also report a strong or significant placebo effect based on the results of several controlled trials (24, 25) . However, there has been no systematic approach to confirming this claim. We hypothesized the placebo response in the treatment of CFS to be higher than or as high as in other medical conditions.
Another aspect of CFS may provide a further window of opportunity into investigating the placebo effect, and more specifically the role of expectation. CFS is a controversial condition, never more so than in the debates about etiology. To put it at its simplest, a large number of sufferers seen in specialist settings or self-help groups have a firm conviction that their illness is of physical origin (26) . For the purposes of this article, the accuracy of such beliefs is irrelevant. It is enough to know they exist and are often strongly held. There is an ongoing debate among professionals about whether this perception is accurate, but we do not intend to say who is right here. The other side of the coin is that, in accepting an organic explanation for their condition-which might be viruses, toxins, infections, allergies and so on-some sufferers equally vehemently reject psychological causation and with it psychological treatments. It is this that gives us an opportunity to test the role of expectation in the placebo response. Thus, interventions based on the assumption of physical causality were hypothesized to have a high placebo effect and those based on the psychological assumption a low effect.
METHODS

Search Strategy
The search strategy aimed to retrieve articles describing clinical trials of any intervention for patients with CFS through the major databases from their inception to August 2002. An extensive systematic review on the treatment of CFS including a highly comprehensive search was available, and studies published until July 2000 were taken from this review (27) . Consequently, our search was limited to the period between January 2000 and August 2002 using Medline, Embase, Cochrane Library, and PsychInfo. A similar search strategy-containing chronic fatigue syndrome, its 17 synonyms, and fibromyalgia-was adopted (Appendix I). The search was updated through December 2002 using PubMed. The bibliographies of the identified studies were searched for additional citations and several experts in the field contacted to retrieve unpublished trials.
Study Selection
To be included in this review, articles were required to meet the following criteria.
1. Type of studies: randomized controlled trials and controlled clinical trials (CCTs)-ie, nonrandomized controlled trials-with a placebo arm according to the definition adopted in the introduction (1 
Data Extraction
Data extraction was focused on the review objectives. The following items were extracted by one reviewer (H.J.C.) and checked by a second (S.W. We classified the type of intervention according to the study hypothesis: high, medium, and low. Interventions based on infectious or immunological assumptions were hypothesized to have a high placebo response and those based on psychological or psychiatric assumptions a low response. Alternative therapies are also popular in CFS patients, and we therefore hypothesized they also would elicit a positive expectancy among CFS patients, and a high placebo response. Finally, other interventions either with an obscure or neutral theoretical background were hypothesized to have a medium placebo response. The former included galanthamine, sulbutiamine, and oral nicotinamide adenine dinucleotide. The latter included hormones, so-called neuroendocrinological agents acting locally on the central nervous system and systemically on the whole body.
When two interventions were tested with a factorial design and consequently there were four arms, the group with the ineffective procedures was selected as the placebo arm. Among the tested interventions, the one expected to elicit a higher placebo response was considered to represent the trial. For example, the trial testing dialyzable leukocyte extract (immunological agent) and cognitive-behavioral therapy (CBT; psychological intervention) simultaneously was considered to be of a high intervention type (28) .
Validity Assessment
Validity assessment of the included studies was conducted according to an available guideline (29) but modified given the objectives of this review. The following criteria were adopted: method of randomization; allocation concealment; participant blinding; investigator blinding; baseline comparability of groups; completeness of follow-up; handling of dropouts and intention-totreat analysis; objectivity of outcome assessment; appropriateness of statistical analysis; sample size calculation; whether the groups were treated identically other than the intervention of interest; and description of placebo type, placebo group, and placebo response. The scoring was 0 for not stated or poor, 1 for adequate, and 2 for good. Participant and investigator blinding was scored as 0 for not stated or no and 1 for yes. In this way, the highest possible score for each study was 22 points. For a CCT, the first two criteria were substituted by appropriateness of control and control for confounding because there was no randomization.
Data Synthesis
All statistical procedures were performed using Stata (Stata Corp., College Station, TX) (30) . First, for each study, we calculated the placebo response by dividing the number of placebo responders by the number of participants assigned to the placebo arm (rather than the number of study completers). If outcome data were provided only on study completers, we assumed that noncompleters had not responded. In order to obtain a pooled placebo response in the treatment of CFS, a meta-analysis was conducted using a random effects model because of the study result heterogeneity. According to the study hypothesis, a preplanned subgroup analysis by intervention type was conducted (31) . Subsequently, meta-regression was performed to investigate further the potential sources of heterogeneity, specifying the method for estimating the between-study variance as restricted maximum likelihood (32) .
In the meta-regression, the dependent variable was the rate of placebo response. The independent variables were the characteristics of each trial defined before the data extraction. They were either categorical or continuous variables: intervention type (low, medium, or high), placebo type (behavioral, oral, or injected), double-blindness (yes or no), participants' mean age, proportion of women, sample size, follow-up duration, publication year, illness duration at baseline, and validity score. Intervention type and placebo type were tested as ordered categories. The rationale to assume an order is self-evident for the former. For the latter, we assumed the described order because usually the more invasive the route of placebo administration, the greater the placebo effect (5). Strictness of criteria for placebo response, a binary variable (strict or loose), was added to this list after the data extraction because of the perceived heterogeneity of measurement systems (Table 1) , indicating more caution in the categorization procedure and interpretation of the results. When a trial had set a more elaborate criterion to designate the response, eg, an increase of 10 points or more in the Karnofsky scale rather than improved or much improved, it was categorized as strict. Separate regressions were conducted for each independent variable. We calculated coefficients that reflect the percent increase in placebo response for each unit increase of the independent variable and the 95% confidence interval (CI) for the coefficient. The p-values for continuous and ordered categorical variables are from tests for trend, which are more powerful than a test of global heterogeneity (31) . The assumptions for the regression models-normal distribution of residuals and homoscedasticity-were tested with residual versus fitted plots and the Cook-Weisberg test. Publication bias was not assessed because of the limited meaning of this procedure, because researchers do not depend on the magnitude of placebo response to publish their studies or not.
RESULTS
The search for 2000 to 2002 yielded 782 references, out of which 28 were initially selected, checking their abstracts for the predetermined relevance criteria . Studies dealing only with fibromyalgia were excluded. Four unpublished studies (61) (62) (63) (64) were identified by contacting several experts in the field of CFS. All of them came to be published later on. Among 28 references of the new search, 6 (33-38) had already been included in the review by Whiting et al. (27) . Consequently, the initial selection included 22 from the new search (39-60), 4 from CFS experts (61-64), 1 from the update using PubMed (65), and 45 from the review by Whiting et al. (28, (33) (34) (35) (36) (37) (38) , yielding 72 in total. Out of these 72 Table  1 , and more details are shown in Appendix II. Only one was a CCT (66) . Out of 28 randomized controlled trials, 6 had a crossover design (49, 70, 73, 75, 96, 97) . In only two trials were the participants recruited from primary care (71, 61) . Six trials did not provide information on setting (49, 68, 73, 80, 83, 96) , but four of these recruited patients with poor baseline functioning or relatively severe illness (49, 68, 80, 83) , and one of them included only the patients with chronic mononucleosis syndrome (73) . The others recruited the participants from secondary care, tertiary care, patient organizations, or advertisements. Very few trials accurately recorded patient attributions, but the sample source suggested they were typical of specialist samples-they were actually from specialist clinics, had poor baseline functioning or had a specific label denoting a physical cause-and were likely to have in general a bias toward physical attributions.
Eight trials had interventions related to a low placebo effect (34 -36,72,77,93,100,103), 5 had medium effect interventions (38, 61, 70, 75, 83) , and 16 had high effect interventions (28,49,56,62,64 -68,71,73,80,90,96,97,102) . Five had used behavioral placebos such as relaxation or standardized medical care and hence were not double-blind (35, 36, 72, 77, 93) , 16 had oral placebo (34, 38, 49, 56, 61, 62, 64, 67, 68, 70, 75, 83, 96, 100, 102, 103) , and 8 had injected placebo (28, 65, 66, 71, 73, 80, 90, 97) . The total number of placebo arm participants was 1016 (median ϭ 32; range ϭ 12-94). Among the participants with known genderonly 27 trials provided the data-70.3% were female. The pro- Many trials had more than two categories-eg, much improved, improved, unchanged, worse, or much worse-but all of them ended up categorizing the subjects into response or no response, and almost all of them reported only the data concerning the binary division. As the initial selection criteria, the outcome was computed only as binary. Twenty-two trials presented general outcomes (28, 34, 38, 49, 56, 61, 62, (65) (66) (67) (68) 70, 71, 73, 75, 77, 80, 83, 96, 97, 100, 102) and seven trials physical outcomes (35, 36, 64, 72, 90, 93, 103) . Study validity varied across the included trials. With 22 the maximum score, the validity ranged between 7 and 21 (median ϭ 17).
Meta-analysis using a random effects model showed the pooled placebo response of 19.6% (95% CI, 15.4 -23.7). The test for heterogeneity was highly significant (p Ͻ .001). Subgroup analysis by intervention type revealed some reduction of the heterogeneity, especially in the high effect intervention category (p ϭ .05; Table 2 ). However, heterogeneity remained significant in all categories. The subgroup analysis also revealed a trend of increased placebo response across the subgroups. Low effect group and medium effect group had a placebo response of 14.0% (95% CI, 8.0% to 19.9%) and 16.5% (5.7% to 27.4%), respectively. As expected, the high effect group presented the highest placebo response (24.0%, 18.9% to 29.1%). Meta-regression produced the following equation:
Mean placebo response ϭ 0.137 ϩ 0.050 ϫ Intervention type (Intervention type was 0 ϭ low, 1 ϭ medium or 2 ϭ high)
The coefficient of 0.050 (95% CI, 0.003-0.097) means there was an average increase of 5.0% in placebo response moving from one category to the next. Intervention type was significantly contributing to the heterogeneity of placebo response (p ϭ .03). We conducted meta-regression for the other potential sources of heterogeneity (Table 3) . Strictness of criteria revealed a marginally significant contribution to heterogeneity (p ϭ .08), but none of the remaining variables did. Regression diagnostics revealed that the assumptions of regression models were met sufficiently.
CONCLUSION
In contrast with the initial hypothesis, the pooled placebo response was substantially lower than the usually reported one third response in other medical conditions. Among the potential sources of heterogeneity we investigated, only the intervention type had a statistically significant contribution to the heterogeneity of placebo response across the trials (p ϭ .03). The second hypothesis was confirmed. Psychological-psychiatric interventions were shown to have a low placebo response, whereas neutral interventions had a medium placebo response. Finally, infectious-immunological and alternativecomplementary interventions were shown to have a high placebo response. This is the first systematic review on the placebo response in the treatment of CFS. It included 29 trials of a variety of interventions in CFS with a wide range of trial level characteristics. The review was hypothesis-driven rather than purely descriptive.
The major limitation of the review was the heterogeneity of the outcome measurement systems across the trials. Different scales and instruments were used to define and measure the endpoint, clinical improvement. Because of this concern, we categorized the trials according to the strictness of response criteria and investigated its contribution to the heterogeneity. The meta-regression showed a marginal effect for strictness of response criteria (p ϭ .08), with studies with very strict criteria having lower placebo response rates. Given this observation, one might also expect an association between study validity and placebo response, which was, however, clearly nonsignificant (p ϭ .77). Unfortunately, it is not clear whether this nonsignificance is actually caused by the nonassociation or the widely commented limitations of the validity assessment (104) . Five trials were not double-blind, which may have led to bias in the assessment of response, but the metaregression showed that this did not contribute to heterogeneity (p ϭ .31).
Another possible limitation which could be pointed out is the meaningfulness of a pooled result from a meta-analysis with high heterogeneity. We did not intend to produce a summary placebo response for clinical purposes, but instead a 
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comparison with pooled placebo responses from the other meta-analyses also with high heterogeneity. This comparison of like with like enabled us to conclude that contrary to the received wisdom, the summary placebo response in CFS was actually lower compared with the comparison disorders. In this sense, the result of this meta-analysis seems to be meaningful. Finally, caution is needed to interpret the findings, because a relatively large number of regression parameters were estimated against a small number of observations (N ϭ 29). This means that the parameters we estimated are imprecise. Had the power of this study been higher, the independent variables with a marginal effect size such as strictness of response criteria and placebo type could have been significant predictors. However, this limitation does not seem to invalidate the meaningfulness of the significant association of intervention type, the main exposure variable of the meta-regression.
Why might the placebo response have been lower than expected in CFS compared with other medical conditions? First, the low placebo response could be a result of low expectation of CFS patients in relation to the interventions in general, because CFS is widely understood to be difficult to treat (27) . Our finding that the type of intervention had an effect on placebo response concords with this explanationthe treatments we anticipated would lead to the lowest expectations of recovery in sufferers also had the lowest placebo responses. Second, the frequently observed lack of a shared belief system between CFS patients and medical professionals could be an explanation for the finding. The therapeutic relationship between patients and clinicians seems to be one of the determinants of the placebo effect (105) . In clinical practice, these differences over attribution and illness models, so frequently observed between medical specialists and CFS patients, can impede the development of a collaborative therapeutic relationship, and this difficulty may extend to clinical trials, lowering the placebo response. Finally, the low placebo response could relate to the natural history of CFS. By definition, it is a chronic condition with duration of at least 6 months. Many of the sufferers entered into trials have illnesses that have lasted many years, and the disorder has a poor prognosis. Researchers have suggested that the response rate in the placebo arm of a clinical trial-placebo response as operationally defined-may include not only the pure placebo effect but also the other components such as spontaneous improvement, regression to the mean, measurement bias, and unidentified parallel interventions (106, 107) . A controversial meta-analysis of the trials comparing placebo with no treatment-an attempt to distinguish the placebo effect from the other components-has found little evidence that placebos had powerful clinical effects, and this seems to accord with the thesis (108) . Given this context, our finding may be partly explained by the low rate of spontaneous remission in CFS.
As mentioned, CFS patients in specialist settings frequently have strong physical attributions and are skeptical about psychological and psychiatric treatments. Concurrently, expectation is the key component of the placebo effect. The present review provides some evidence to link these two established research findings. Psychological-psychiatric interventions showed a lower placebo response, possibly because of patients' lower expectations.
At the clinical practice level, the finding of the overall low placebo response emphasizes the need to enhance the nonspecific effects in the current treatment of CFS. Contextual factors such as a collaborative therapeutic relationship should be maximized in the management of CFS, hence increasing the overall effect of an active treatment, which consists of an active component and a nonspecific component-the placebo effect. The role of contextual factors may be even more critical for CBT, graded exercise therapy (GET), and antidepressants, because at least CBT and GET are validated treatments for CFS (27) and antidepressants effective for comorbid depression in both physical and psychological disorders (109) . It is of course both intriguing and paradoxical to note the disconnection between expectations of improvement and the actual effectiveness of interventions such as CBT and GET-an area worthy of closer study, perhaps using observation methods. Whatever explanation is favored, the clinical implication is the need to provide existing evidence supportive of CBT and GET in a language accessible to patients, and if antidepressants are to be used, to make it clear that this is a treatment for depression rather than CFS itself. These strate- 
